AdvanCell
AdvanCell develops targeted alpha radiopharmaceuticals for cancer using Lead-212, with integrated isotope supply and manufacturing.
$315MSeries D
Role not disclosedAW
Alpha Wave
Activity from announced rounds
Activity in this selectionAustralia · Oct 23, 2026 · Jan 1, 2026
Alpha Wave is the investment-manager name used in the covered financings and connected to Alpha Wave Global’s official press and investment records.
Recorded funding activity
The recorded activity includes a lead role in Moonwalk Biosciences’ Series B for medicines targeting fat-tissue pathways in obesity and cardiometabolic disease. Other announcements concern AdvanCell’s targeted alpha radiopharmaceuticals for cancer and Ultrahuman’s wearable ring and health-testing products. These events describe the activity captured here rather than the manager’s complete allocation.
- Rounds participated in
- 1
- Confirmed lead rounds
- — 1 roles undisclosed
- New companies
- 1 First participation on record · 0 follow-on
- Funding in participating rounds
- $315M 1 disclosed · full round size, not this investor’s share